Brain scans reveal clues about Parkinson's and serotonin
NCT ID NCT05916625
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study examined how a specific serotonin receptor (5-HT4) is expressed in the brains of people with mild to moderate Parkinson's disease compared to healthy older adults. Researchers used PET scans and a special tracer to measure receptor levels, alongside cognitive and motor tests. The goal was to better understand how changes in this receptor relate to both movement and non-movement symptoms. No treatment was given; it was purely an observational imaging study.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help researchers better understand the role of serotonin receptors in Parkinson's disease, potentially pointing toward new targets for symptom management.
- What could go wrong
- This is an early exploratory study with only 40 participants, so results may not apply to all Parkinson's patients. It does not test any treatment, so no direct benefit is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Man or woman : Age between ≥ 50 and ≤ 85 years old * For women: postmenopausal * Affiliated to a social security scheme or similar; * Having given written consent to participate in the free and informed study. * Level of study: ≥ 6 years of schooling * only for healthy volunteer : No history of neurological or psychiatric disease * Only for patient : Having a clinically established or probable diagnosis of Parkinson's disease according to the criteria defined by the Movement Disorder Society at a Hoehn and Yahr stage ≤ 3 (in on dopa conditions) and a duration of evolution of the disease between 2 and 8 years. * Only for patient : Having a MoCA (Montreal Cognitive Assessment) ≥ 20/30. Exclusion Criteria: * Diagnosis other than Parkinson's disease ( for patient only) * Treated with specific serotonin inhibitors (SSRIs), specific noradrenaline inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) and neuroleptics in the last 3 months * Use of recreational drugs interfering with the serotonergic system (ecstasy, MDMA) or opioids (cannabis, opiates) in the last 3 months or chronic use * Contraindication to magnetic resonance imaging (MRI) or positron emission tomography (PET) * Participation in the last year to a study using ionizing radiation or concomitant participation in another research project involving the human being that may interfere with the results or the conclusions of this study * Exceeding the annual amount of compensation authorized for participation in research protocols * Deprivation of liberty by judicial or administrative decision, person subject to a legal protection measure * BMI ≥ 35kg/m2 * Presence of depression (BDI-2 score ≥21), anxiety (Parkinson Anxiety Scale (PAS) score ≥14) or apathy (STARKSTEIN score ≥14) - (for healthy volunteers only) * Cognitive impairment (MOCA score ≤26) (for healthy volunteers only) * Current or past neurological or psychiatric pathology (for healthy volunteers only) * Serious and progressive medical pathology * Current or past dependence on any addictive substance according to DSM-V (The Diagnostic and Statistical Manual of Mental Disorders) criteria (alcohol, cannabis, hallucinogens, inhalants, opiates, sedatives, stimulants), except tobacco and caffeine. (for healthy volunteers only)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CERMEP
Bron, 69500, France
-
Hôpital des Charpennes Centre de Recherche Clinique "Vieillissement-Cerveau-Fragilité"
Lyon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Giving Parkinson's patients a say may boost their Brain's ability to learn movement
- Brain scans probe why some Parkinson's patients freeze Mid-Step
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a workout after walking practice help Parkinson's patients learn better?